Payment overview · 2025
General Payments
$1,473.84
59 reported records · 22 companies
Healthcare provider profile · identity verified
Randy Hines, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SMYRNA, GA · NPI 1235542754
Verified facts
What the public records show
CMS Open Payments records show Randy Hines, M.D. received $1,473.84 in general payments during 2025 across 59 reported records.
Astellas Pharma US Inc accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Ozempic, Shingrix.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $244.70 | 16.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $219.34 | 14.9% | 7 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $127.26 | 8.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $118.92 | 8.1% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $97.30 | 6.6% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $94.58 | 6.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.34 | 5.0% | 4 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $55.62 | 3.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.97 | 3.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.96 | 3.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.92 | 3.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $43.91 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.79 | 2.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.77 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.49 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.17 | 1.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.95 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.15 | 1.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.68 | 1.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $21.78 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.89 | 1.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.35 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,473.84 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $244.70 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $159.35 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $127.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.12 | 6 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $94.58 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $93.22 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $73.34 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $73.34 | 4 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $55.62 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $43.91 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $31.79 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.17 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $6.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 13 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 173 | 55 |
| Metformin Hcl | Metformin Hcl | 160 | 49 |
| Lisinopril | Lisinopril | 95 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 25 |
| Nifedipine Er | Nifedipine | 80 | 31 |
| Gabapentin | Gabapentin | 70 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Losartan Potassium | Losartan Potassium | 54 | 26 |
| Omeprazole | Omeprazole | 45 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 11 |
| Carvedilol | Carvedilol | 35 | 15 |
| Finasteride | Finasteride | 34 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | 15 |
| Glipizide | Glipizide | 30 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | 11 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | 13 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Temazepam | Temazepam | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Furosemide | Furosemide | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,473.84 · 59 records | Astellas Pharma US Inc | ACCRUFER, AIRSUPRA, APRETUDE, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, DUPIXENT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, INSPIRE, JARDIANCE, MOUNJARO, NEFFY, NURTEC ODT, OFEV, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TZIELD, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error